Boston Scientific touts 1-year data on Vercise DBS in Parkinson ’ s

This study meets a new level of rigor in evaluating the effectiveness of a DBS system,” coordinating principal investigator Dr. Jerrold Vitek, of the University of Minnesota Medical School, said in prepared remarks. “The double-blind design gives us confidence that the improvements in patients on time with good symptom control, as evaluated by the diary data, are an objective measure of the outcomes and suggests patients will benefit from the Vercise System.” Vercise won CE Mark approval in the European Union to treat essential tremor in 2014. FDA approval to treat Parkinson’s followed last December, backed by data from the Intrepid study. The post Boston Scientific touts 1-year data on Vercise DBS in Parkinson’s appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Neuromodulation/Neurostimulation Boston Scientific Parkinson's disease Source Type: news